On January 16, 2015, the famous young singer Yao Beina died of breast cancer and died at the age of 33;
On April 6, 2009, the famous healing singer Asan, who died of breast cancer, died at the age of 34;
On May 13, 2007, the 87 version of "Dream of Red Mansions", the singer of the jade, Chen Xiaoxu died of breast cancer, only 42 years old...
Inadvertently, breast cancer has taken so many fresh lives, and we should be alarmed at the same time, should we ring the alarm? According to the Breast Cancer Incidence Data released by the National Cancer Center and the Ministry of Health's Disease Prevention and Control Bureau in 2012, the incidence of breast cancer in the national cancer registration area ranks first among female malignant tumors, and the incidence rate has increased significantly in recent years. There are about 470,000 patients in China. After 20 years, breast cancer will be the most common malignant tumor in China.
The key to breast cancer prevention and treatment is early detection. Early breast cancer, especially zero-stage breast cancer, can be cured by surgery, and the cost can be cured. The 5-year survival rate can reach more than 90%. In the middle of breast cancer, if you receive formal treatment, the cure rate is only about 50%. In advanced stage of breast cancer, the condition is more serious, and the cancer cells spread a lot. It is difficult to cure and can only prolong life by treatment.
Practice has shown that regular breast cancer screening for women of the right age is the best way to improve the cure rate of early breast cancer. The symptoms of early breast cancer are relatively concealed, the lesions are small, routine physical examination is difficult to find, X-ray examination can find early lesions of 0.1mm, so it is the gold standard for breast cancer screening.
From 1973 to 1980, the American Oncology Association and the National Cancer Institute further implemented a breast cancer screening program, which concluded that regular breast cancer screening (mammography) can reduce breast cancer mortality. Nowadays, women over the age of 35 have done mammography every year in developed countries such as Europe and the United States, and the threat of breast cancer to women in these countries has been greatly reduced.
The author understands that breast cancer is showing a high incidence in China, and the probability of breast cancer diagnosis in China is less than 20% in the early stage. Most patients are found in the middle and late stages, and the situation is very serious. This aspect is because the public's cancer health check is not strong, and on the other hand, due to the lack of professional doctors, it is difficult to comprehensively promote breast cancer screening at the grassroots level.
With the gradual maturity of artificial intelligence technology, the use of AI-assisted diagnostic technology for breast cancer assisted diagnosis and screening is a feasible way to improve the survival rate of breast cancer in China. The protagonist of today's story, Yibao Technology, is a AI-assisted diagnosis. Technology, the startup company for breast cancer screening, founder Zhou Ming is a technical expert in artificial intelligence returned from studying in the United States.
High-tech entrepreneurs
When studying at Tsinghua University in the 1990s, Zhou Ming had already been exposed to neural networks, and it was a hot topic in the academic world to let computers follow the way of thinking in the human brain. After graduation, Zhou Ming stayed in charge of the teaching and research work of the Computing Center of the Environmental College. He became the first system engineer (MCSE) certified by Microsoft in China and participated in the construction of the first provincial-level information system in China. In order to further study advanced technology, he obtained a full scholarship from the University of Cincinnati, USA, and obtained a master's degree in engineering and a master's degree in business administration in the United States.
He has worked in international IT giants such as the International Computer Alliance (CA) and IBM for more than a decade, and has many years of experience in continuing entrepreneurship. At the time, CA was the third-largest independent software company in the world. Headquartered in New York, USA, he participated in the development of Neugent, the industry's first neural network business software, using neural networks to explore business value. At that time, it was called data warehouse, not called big data, and belonged to BI (Business Intelligence) field.
At IBM, he was responsible for the development and operation of several Business Analytics product lines, leading a team of nearly 100 people around the world, covering the PC, mobile and cloud.
His partner, an alumnus of the Department of Electronic Engineering at Tsinghua University, received his Ph.D. in image processing from Stony Brook University in New York, USA, focusing on the research of medical image algorithms and published papers in the world's top journal Science. Zhou Ming said that they have complementary advantages, one is responsible for algorithms and models, and the other is responsible for product engineering and commercialization.
Speaking of returning to China, Zhou Ming told the art network that in fact many college students have the idea of ​​starting a business after graduation. With the purpose of learning modern advanced technology, it is natural to go to study abroad to accumulate experience. After years of accumulation of technology and experience, they return to the motherland to realize their dreams through entrepreneurship. After more than 30 years of reform and opening up, although China's economy has grown at a high speed, it still has a large gap with advanced countries in the fields of medical health, and the phenomenon of difficulty in seeing people is widespread.
Zhou Ming believes that the application of modern artificial intelligence technology can help solve the problem of lack of medical resources and uneven distribution in China. AI is inevitably the key technology to promote graded diagnosis and treatment and cancer screening. Therefore, on July 1, 2015, Yibao Technology was formally established. Through the combination of medical imaging and artificial intelligence, the entry point was locked into breast cancer AI. Artificial intelligence was used to analyze breast images to assist doctors in diagnosis.
Zhou Ming participated in the 2016 China International Hi-Tech Fair
Pathological Diagnostic Solutions
LBC, AI-assisted Diagnosis, Pathology Slide Scanner
HANGZHOU DIAN BIOTECHNOLOGY CO., LTD. , https://www.dianbiotech.com